Candel Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:CADL

Comments

Candel Therapeutics Inc Earnings Estimates

CADLNASDAQ

Trade with Public

$5.10

0.234.72%

At close: Apr 13, 5:00 PM EST

$5.10

0.234.72%

Pre-Market: 8:22 AM EST

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Candel Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:CADL

Candel Therapeutics (CADL) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.30 and quarterly revenue of N/A.

In the most recent quarter (Q4), Candel Therapeutics reported EPS of $-0.54, missing estimates of $-0.24 by 1.25%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Candel Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Candel Therapeutics has averaged an EPS surprise of 0.87% and a revenue surprise of 0.00%.

Earnings Date

May 12

EPS Estimate

$-0.300

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

–

Candel Therapeutics Earnings History

Analyze the earnings history of Candel Therapeutics using advanced sorting and filters.

Loading calendar...

Candel Therapeutics (CADL) Earnings Per Share

The chart below shows Candel Therapeutics's reported EPS compared to analyst estimates over recent quarters.

Candel Therapeutics (CADL) Revenue

The chart below shows Candel Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Candel Therapeutics (NASDAQ:CADL) reporting earnings?

Candel Therapeutics (CADL) is scheduled to report earnings on May 12, 2026. The last reported earnings were for reported on March 12, 2026 for Q4.

What were the latest earnings per share (EPS) for Candel Therapeutics (NASDAQ:CADL)?

The Actual EPS was $-0.54, which missed the estimate of $-0.24.

What were Candel Therapeutics’s (NASDAQ:CADL) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL

$5.18

-0.48%

Monopar Therapeutics Inc

DiaMedica Therapeutics Inc

Candel Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:CADL

Candel Therapeutics (CADL) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.30 and quarterly revenue of N/A.

In the most recent quarter (Q4), Candel Therapeutics reported EPS of $-0.54, missing estimates of $-0.24 by 1.25%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Candel Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Candel Therapeutics has averaged an EPS surprise of 0.87% and a revenue surprise of 0.00%.

Earnings Date

May 12

EPS Estimate

$-0.300

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

–